Bristol-Meyers Squibb Announces ORENCIA Shows Comparable Efficacy to Humira in Year Two Ample Study

Bristol-Myers Squibb Company BMY today announced the results of year two data from AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve rheumatoid arthritis (RA) Subjects With Background Methotrexate), a first-of-its-kind trial of 646 patients comparing the subcutaneous (SC) formulation of ORENCIA® (abatacept) vs. Humira® (adalimumab), each on a background of MTX, in biologic naïve patients with moderate to severe RA. The AMPLE year two data are being presented this week at the European League Against Rheumatism (EULAR) annual congress and highlighted during a congress press conference. AMPLE met its primary endpoint as measured by non-inferiority of ACR20 See full press release